Author Question: A nurse is caring for a patient admitted to the unit and receiving dantrolene (Dantrium) for ... (Read 52 times)

cdr_15

  • Hero Member
  • *****
  • Posts: 546
A nurse is caring for a patient admitted to the unit and receiving dantrolene (Dantrium) for spasticity. The nurse should particularly monitor the patient's
 
  a. liver enzymes.
  b. renal function tests.
  c. complete blood count.
  d. serum electrolytes.

Question 2

Intravenous dantrolene (Dantrium) 2 mg/kg is prescribed for preoperative prophylaxis for a patient with a history of malignant hyperthermia. The patient weighs 132 lb. The nurse administer _____ mg.
 
  What will be an ideal response?



sylvia

  • Sr. Member
  • ****
  • Posts: 331
Answer to Question 1

ANS: A
Hepatotoxicity is a serious potential problem in a patient receiving dantrolene, and baseline liver enzymes should be obtained prior to dosing and periodically thereafter.
There is no indication that renal function tests, a complete blood cell count, or electrolytes should be monitored in a patient receiving dantrolene.

Answer to Question 2

ANS:
120
132 lb = x kg
2.2 lb  132 lb
1 kg x
2.2y = 132
x = 60 kg
2 mg  x
1 kg 60
x = 120 mg



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
 

Did you know?

To maintain good kidney function, you should drink at least 3 quarts of water daily. Water dilutes urine and helps prevent concentrations of salts and minerals that can lead to kidney stone formation. Chronic dehydration is a major contributor to the development of kidney stones.

Did you know?

Critical care patients are twice as likely to receive the wrong medication. Of these errors, 20% are life-threatening, and 42% require additional life-sustaining treatments.

Did you know?

The first war in which wide-scale use of anesthetics occurred was the Civil War, and 80% of all wounds were in the extremities.

Did you know?

Essential fatty acids have been shown to be effective against ulcers, asthma, dental cavities, and skin disorders such as acne.

Did you know?

Bisphosphonates were first developed in the nineteenth century. They were first investigated for use in disorders of bone metabolism in the 1960s. They are now used clinically for the treatment of osteoporosis, Paget's disease, bone metastasis, multiple myeloma, and other conditions that feature bone fragility.

For a complete list of videos, visit our video library